About
Twist Bioscience Corporation's expertise is synthetic DNA. The company developed a proprietary, semiconductor-based synthetic-DNA manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools such as oligonucleotides, genes, pathways, chassis, and genomes. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, theplatform overcomes the current inefficiencies of synthetic DNA production and enables cost-effective, rapid, high-quality, and high-throughput synthetic gene production. Following the 2016 acquisition of Genome Compiler Corporation, a provider of software for genetic engineers and molecular and synthetic biologists, the company establisheda researchand development center in Tel Aviv. This acquisition soughtto leverage Genome Compiler's technology to drive a digital product portfolio, including an eCommerce solution with gene design capabilities. Theproducts will enable Twist Bioscience's customers to reimagine their research by providing seamless integration of the design and build of their synthetic DNA.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Twist Bioscience become a public company and on which exchange?
- Twist Bioscience went public on NASDAQ in October 2018, trading under the ticker TWST.
- What was a key strategic development for Twist Bioscience in 2016?
- In October 2016, Twist Bioscience acquired Genome Compiler Corporation, an Israeli provider of software for genetic engineers and molecular and synthetic biologists.
- What was the purpose of Twist Bioscience's acquisition of Genome Compiler Corporation?
- The acquisition of Genome Compiler Corporation aimed to leverage its technology to develop a digital product portfolio, including an eCommerce solution with gene design capabilities, to integrate the design and build of synthetic DNA for customers.
- When did Twist Bioscience establish a research and development center in Tel Aviv?
- Twist Bioscience established a research and development center in Tel Aviv in April 2016, following the acquisition of Genome Compiler Corporation.
- What is Twist Bioscience's primary area of expertise?
- Twist Bioscience's primary expertise is synthetic DNA, utilizing a proprietary, semiconductor-based manufacturing process.
- How does Twist Bioscience's technology improve synthetic DNA production?
- Twist Bioscience uses a 10,000-well silicon platform for synthetic DNA manufacturing, which overcomes inefficiencies of traditional 96-well plastic plates, enabling cost-effective, rapid, high-quality, and high-throughput synthetic gene production.
- What was the reported amount raised by Twist Bioscience in its October 2018 IPO?
- According to an Xconomy report from November 2018, Twist Bioscience's IPO hauled in $70 million for its DNA synthesis technology.
- What is the approximate global employee count for Twist Bioscience?
- Twist Bioscience has an approximate global employee count of 1,001-5,000, with an exact count of 1157 worldwide.